Press "Enter" to skip to content

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC) – Business Wire

admin 0

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)  Business Wire

KEYTRUDA is First Anti-PD-1 Therapy Approved as Part of a Combination Regimen in Europe for RCC Across All IMDC Risk Groups. September 04, 2019 …

“cervical cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *